OncoHost to Showcase Plasma Proteomics Research in NSCLC at AACR 2025

Original source here.

OncoHost to Showcase Plasma Proteomics Research in NSCLC at AACR 2025

New Data Sheds Light on Mechanisms of Immunotherapy Resistance and Supports Development of Personalized Treatment Strategies

BINYAMINA, Israel and CARY, N.C. , April 23, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved cancer patient outcomes, today announced its acceptance to present a scientific poster at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30, 2025, in Chicago, IL.

The abstract, titled "Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors," investigates the proteins involved in the PROphetNSCLC™ model. PROphetNSCLC™ serves as a treatment guidance tool for patients with advanced stage non-small cell lung cancer (NSCLC). The study is the result of an international collaboration between academic institutions and leading cancer centers including The Ohio State University, UC Davis, Baylor University Medical Center, Roswell Park Comprehensive Cancer Center, and others.

"This research provides a deeper understanding of the biological underpinnings driving resistance to immunotherapy in NSCLC," said Dr. Michal Harel, Director of Science and Innovation at OncoHost and lead author of the study. "Our analysis of resistance-associated proteins (RAPs) identifies key proteomic signatures that not only explain clinical outcomes but can also help stratify patients and identify new therapeutic targets."

PROphetNSCLC™ is based on 388 plasma proteins, collectively termed RAPs. The study uncovered five distinct expression patterns across healthy individuals, NSCLC patients with clinical benefit (CB), and those with no clinical benefit (NCB) from immunotherapy. These patterns revealed mechanistic insights into treatment resistance that can be monitored in the plasma, highlighting processes such as angiogenesis, immune modulation, chemoresistance, and cell proliferation. In addition, the findings shows that 17.5% of the RAPs identified could be targeted with existing or investigational drugs. These findings suggest that RAPs can serve as a pool of novel targets for intervention, further strengthening the potential clinical significance of these RAPs.

"Being selected to present at AACR reinforces the scientific and clinical relevance of our work," said Ofer Sharon, MD, CEO of OncoHost. "We are moving beyond predictive diagnostics into an era where understanding the 'why' behind treatment resistance is critical to driving real-world precision medicine. This study brings us closer to realizing the full potential of proteomics in oncology."

Poster Presentation Details
Title: Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors
Session Title: Predictive Biomarkers 3
Poster Board #: 27
Presenter: Michal Harel, PhD, Director of Science and Innovation, OncoHost
Date & Time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CDT

The abstract is available on the AACR website here.

About OncoHost      
OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina, transforming the approach to precision medicine for improved patient outcomes. OncoHost's proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, Facebook, and YouTube.

‍